| Structure |
Catalog |
Product Name |
CAS |
E3 Ligase |
Target |
Inquiry |
 |
BPL-202053 |
5-(4-(3-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)piperazin-1-yl)-N-((3S,5S)-1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)-5-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyrrolidin-3-yl)pyrazine-2-carboxamide |
2126803-20-9 |
IAP |
RIPK2 |
Inquiry |
|
Molecular Weight: 1063.34
Molecular Formula: C54H74N14O7S
Boiling Point: 1259.6±65.0°C at 760 Torr
Density: 1.35±0.1 g/cm3
Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
|
![(5S,8S,10aR)-3-(5-(4-(3-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carbonyl)-5-((S)-2-(methylamino)propanamido)-6-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)decahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide](https://resource.bocsci.com/structure/2126803-46-9.gif) |
BPL-202054 |
(5S,8S,10aR)-3-(5-(4-(3-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carbonyl)-5-((S)-2-(methylamino)propanamido)-6-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)decahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide |
2126803-46-9 |
IAP |
RIPK2 |
Inquiry |
|
Molecular Weight: 1047.29
Molecular Formula: C53H70N14O7S
Density: 1.39±0.1 g/cm3
Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
|
![1-(2-((2R,5R)-2-(((R)-4-(5-(4-(3-((6-(tert-Butylsulfonyl)-4-((3,4-dimethyl-1H-pyrazol-5-yl)amino)quinazolin-7-yl)oxy)propyl)piperazine-1-carbonyl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)methyl)-5-methylpiperazin-1-yl)acetyl)-6-(4-fluorobenzyl)-3,3,4-trimethyl-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-b]pyridin-5-one](https://resource.bocsci.com/structure/2143956-44-7.gif) |
BPL-202055 |
1-(2-((2R,5R)-2-(((R)-4-(5-(4-(3-((6-(tert-Butylsulfonyl)-4-((3,4-dimethyl-1H-pyrazol-5-yl)amino)quinazolin-7-yl)oxy)propyl)piperazine-1-carbonyl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)methyl)-5-methylpiperazin-1-yl)acetyl)-6-(4-fluorobenzyl)-3,3,4-trimethyl-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-b]pyridin-5-one |
2143956-44-7 |
IAP |
RIPK2 |
Inquiry |
|
Molecular Weight: 1144.44
Molecular Formula: C59H78FN15O6S
Density: 1.38±0.1 g/cm3
Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
|
![2-((2R,5R)-2-(((R)-4-(5-(4-(3-((6-(tert-Butylsulfonyl)-4-((3,4-dimethyl-1H-pyrazol-5-yl)amino)quinazolin-7-yl)oxy)propyl)piperazine-1-carbonyl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)methyl)-5-methylpiperazin-1-yl)-1-(6-(4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)ethan-1-one](https://resource.bocsci.com/structure/2143956-15-2.gif) |
BPL-202056 |
2-((2R,5R)-2-(((R)-4-(5-(4-(3-((6-(tert-Butylsulfonyl)-4-((3,4-dimethyl-1H-pyrazol-5-yl)amino)quinazolin-7-yl)oxy)propyl)piperazine-1-carbonyl)pyrimidin-2-yl)-2-methylpiperazin-1-yl)methyl)-5-methylpiperazin-1-yl)-1-(6-(4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)ethan-1-one |
2143956-15-2 |
IAP |
RIPK2 |
Inquiry |
|
Molecular Weight: 1114.41
Molecular Formula: C58H76FN15O5S
Density: 1.267±0.06 g/cm3
Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
|
 |
BPL-202057 |
PP1 |
2471968-44-0 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1544.36
Molecular Formula: C76H94ClF3N10O11S4
Density: 1.40±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202058 |
PP2 |
2471968-46-2 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1558.39
Molecular Formula: C77H96ClF3N10O11S4
Density: 1.39±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202059 |
PP3 |
2474076-11-2 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1572.42
Molecular Formula: C78H98ClF3N10O11S4
Density: 1.39±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202060 |
PP4 |
2471968-49-5 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1586.44
Molecular Formula: C79H100ClF3N10O11S4
Density: 1.38±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202061 |
PP5 |
2474076-12-3 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1600.47
Molecular Formula: C80H102ClF3N10O11S4
Density: 1.37±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202062 |
PP6 |
2471968-69-9 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1614.47
Molecular Formula: C81H104ClF3N10O11S4
Density: 1.37±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202063 |
PP7 |
2474076-13-4 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1628.52
Molecular Formula: C82H106ClF3N10O11S4
Density: 1.36±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202064 |
PP8 |
2471968-70-2 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1642.55
Molecular Formula: C83H108ClF3N10O11S4
Density: 1.35±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202065 |
PZ703a |
2471970-55-3 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1600.47
Molecular Formula: C80H102ClF3N10O11S4
Density: 1.37±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202066 |
PZ703b |
2471970-56-4 |
VHL |
BCL-xL |
Inquiry |
|
Molecular Weight: 1600.47
Molecular Formula: C80H102ClF3N10O11S4
Density: 1.37±0.1 g/cm3
Description: It is a novel BCL-XL PROTAC degrader with enhanced inhibition of BCL-2.
|
 |
BPL-202067 |
4-((2-(3-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
2353492-61-0 |
CRBN |
ALK |
Inquiry |
|
Molecular Weight: 941.43
Molecular Formula: C46H54ClN10O8P
Density: 1.44±0.1 g/cm3
Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
|
 |
BPL-202068 |
4-((2-(2-(3-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
2353492-62-1 |
CRBN |
ALK |
Inquiry |
|
Molecular Weight: 985.48
Molecular Formula: C48H58ClN10O9P
Density: 1.43±0.1 g/cm3
Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
|
 |
BPL-202069 |
4-((2-(2-(2-(3-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
2353492-65-4 |
CRBN |
ALK |
Inquiry |
|
Molecular Weight: 1029.53
Molecular Formula: C50H62ClN10O10P
Density: 1.42±0.1 g/cm3
Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
|
 |
BPL-202070 |
4-((15-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
2353492-66-5 |
CRBN |
ALK |
Inquiry |
|
Molecular Weight: 1073.59
Molecular Formula: C52H66ClN10O11P
Density: 1.40±0.1 g/cm3
Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
|
 |
BPL-202071 |
4-((18-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-18-oxo-3,6,9,12,15-pentaoxaoctadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
2353492-67-6 |
CRBN |
ALK |
Inquiry |
|
Molecular Weight: 1117.64
Molecular Formula: C54H70ClN10O12P
Density: 1.39±0.1 g/cm3
Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
|
 |
BPL-202072 |
SIAIS164018 |
2353492-68-7 |
CRBN |
ALK
ALK G1202R
EGFR L858R/T790M
FAK
PTK2B
PTK6
FER
RPS6KA1 |
Inquiry |
|
Molecular Weight: 883.35
Molecular Formula: C43H48ClN10O7P
Density: 1.48±0.1 g/cm3
Description: SIAIS164018 is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile. SIAIS164018 can degrade not only ALK fusion proteins in activating or G1202R-mutated form but also mutant EGFR with L858R+ T790M, which are two most important targets in non-small-cell lung cancer. SIAIS164018 strongly inhibits cell migration and invasion of Calu-1 and MDA-MB-231. SIAIS164018 degrades several important oncoproteins involved in metastasis such as FAK, PYK2, and PTK6.
|
